The results showed that the docking energy values of AKT1, MMP9, STAT3, SRC, and EGFR were all less than − 7.0 kcal/mol, indicating that they had strong binding activity, suggesting that it was predicted that dexamethasone could have the treatment of thymoma-associated myasthenia gravis via AKT1, MMP9, STAT3, SRC, EGFR, and other targets. The gene discussed is AKT1; the disease is thymoma.